296 related articles for article (PubMed ID: 19095367)
1. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy.
Dehing-Oberije C; Yu S; De Ruysscher D; Meersschout S; Van Beek K; Lievens Y; Van Meerbeeck J; De Neve W; Rao B; van der Weide H; Lambin P
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):355-62. PubMed ID: 19095367
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325).
Dehing-Oberije C; Aerts H; Yu S; De Ruysscher D; Menheere P; Hilvo M; van der Weide H; Rao B; Lambin P
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):360-8. PubMed ID: 20888135
[TBL] [Abstract][Full Text] [Related]
3. Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy.
Stinchcombe TE; Morris DE; Moore DT; Bechtel JH; Halle JS; Mears A; Deschesne K; Rosenman JG; Socinski MA
Lung Cancer; 2006 Apr; 52(1):67-74. PubMed ID: 16499996
[TBL] [Abstract][Full Text] [Related]
4. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy.
Dehing-Oberije C; De Ruysscher D; van der Weide H; Hochstenbag M; Bootsma G; Geraedts W; Pitz C; Simons J; Teule J; Rahmy A; Thimister P; Steck H; Lambin P
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1039-44. PubMed ID: 17889446
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume.
Basaki K; Abe Y; Aoki M; Kondo H; Hatayama Y; Nakaji S
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):449-54. PubMed ID: 16226400
[TBL] [Abstract][Full Text] [Related]
6. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.
Cho KH; Ahn SJ; Pyo HR; Kim KS; Kim YC; Moon SH; Han JY; Kim HT; Koom WS; Lee JS
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1397-404. PubMed ID: 19117690
[TBL] [Abstract][Full Text] [Related]
7. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy.
Chang JY; Komaki R; Sasaki R; Liao Z; Stevens CW; Lu C; Fossella FV; Allen PK; Cox JD; Spitz MR; Wu X
Clin Cancer Res; 2005 Apr; 11(8):2894-8. PubMed ID: 15837739
[TBL] [Abstract][Full Text] [Related]
8. Probability of mediastinal involvement in non-small-cell lung cancer: a statistical definition of the clinical target volume for 3-dimensional conformal radiotherapy?
Giraud P; De Rycke Y; Lavole A; Milleron B; Cosset JM; Rosenzweig KE
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):127-35. PubMed ID: 16226394
[TBL] [Abstract][Full Text] [Related]
9. High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer.
Zhao L; West BT; Hayman JA; Lyons S; Cease K; Kong FM
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):103-10. PubMed ID: 17363189
[TBL] [Abstract][Full Text] [Related]
10. Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer.
Werner-Wasik M; Swann RS; Bradley J; Graham M; Emami B; Purdy J; Sause W
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):385-90. PubMed ID: 17869017
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival after non-small cell lung cancer surgery: development and validation of a prognostic model with a preoperative and postoperative mode.
Birim O; Kappetein AP; Waleboer M; Puvimanasinghe JP; Eijkemans MJ; Steyerberg EW; Versteegh MI; Bogers AJ
J Thorac Cardiovasc Surg; 2006 Sep; 132(3):491-8. PubMed ID: 16935100
[TBL] [Abstract][Full Text] [Related]
12. Impact of comorbidity and age on the outcome of patients with inoperable NSCLC treated with concurrent chemoradiotherapy.
Semrau S; Klautke G; Virchow JC; Kundt G; Fietkau R
Respir Med; 2008 Feb; 102(2):210-8. PubMed ID: 17980571
[TBL] [Abstract][Full Text] [Related]
13. Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer.
Kim DW; Shyr Y; Chen H; Akerley W; Johnson DH; Choy H
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1029-36. PubMed ID: 15913910
[TBL] [Abstract][Full Text] [Related]
14. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT).
Wang S; Liao Z; Wei X; Liu HH; Tucker SL; Hu CS; Mohan R; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1399-407. PubMed ID: 16997503
[TBL] [Abstract][Full Text] [Related]
15. Survival of patients in clinical stages I-IIIb of non-small-cell lung cancer treated with radiation therapy alone. Results of a population-based study in Southern Saxony-Anhalt.
Bollmann A; Blankenburg T; Haerting J; Kuss O; Schütte W; Dunst J; Neef H;
Strahlenther Onkol; 2004 Aug; 180(8):488-96. PubMed ID: 15292969
[TBL] [Abstract][Full Text] [Related]
16. Time trends in nodal volumes and motion during radiotherapy for patients with stage III non-small-cell lung cancer.
Bosmans G; van Baardwijk A; Dekker A; Ollers M; Wanders S; Boersma L; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):139-44. PubMed ID: 17996384
[TBL] [Abstract][Full Text] [Related]
17. Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemoradiotherapy.
Sekine I; Sumi M; Ito Y; Tanai C; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
Jpn J Clin Oncol; 2009 Nov; 39(11):707-12. PubMed ID: 19692418
[TBL] [Abstract][Full Text] [Related]
18. Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy.
Alexander BM; Othus M; Caglar HB; Allen AM
Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1381-7. PubMed ID: 20605346
[TBL] [Abstract][Full Text] [Related]
19. Baseline cardiopulmonary function as an independent prognostic factor for survival of inoperable non-small-cell lung cancer after concurrent chemoradiotherapy: a single-center analysis of 161 cases.
Semrau S; Klautke G; Fietkau R
Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):96-104. PubMed ID: 20350789
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in stage III non-small-cell lung cancer.
Ademuyiwa FO; Johnson CS; White AS; Breen TE; Harvey J; Neubauer M; Hanna NH
Clin Lung Cancer; 2007 Sep; 8(8):478-82. PubMed ID: 17922971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
